Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: ok who wrote (931)	6/4/1999 6:30:00 AM
From: dalroi	Respond to of 1073

quite correct HRT is a hughe market in potential BUT 1/ not all women take hrt letst face it 10-15 % start with it 2/ hughe drop out rate > 50 % 3/ lots of competition i know at least 20 products going from livial, kliogest, low dose oc pills, oestrogel, 4 types of patches etc.. not one has a 10 % 4/ price of products are not comparable with cardiac or gi medicatio,s eg livial is consederd expensisve in belgium and sells for 1$ a day total market in belgium should be arround 60 000 000 bfr divide by 40 to get $ ie 1500 000 $ on a population of 10 000 000 which in us should be 250 000 000 people 40 000 000 which one has to divide by 20 ie each +- 2 000 000 brutto is this viable ???? either way i thank you for the response if you see a major flauw in this please tell me then ill buy but untill then i wxait dalroi